中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study

文献类型：期刊论文

作者Chen, Xiaozhong2; Wang, Wei3,4; Zou, Qingfeng5; Zhu, Xiaodong6,7,8; Lin, Qin9; Jiang, Yi10; Sun, Yan11; Shen, Liangfang12; Wang, Lin13; Zou, Guorong14
刊名SIGNAL TRANSDUCTION AND TARGETED THERAPY
出版日期2024-06-19
卷号9
ISSN号2095-9907
DOI10.1038/s41392-024-01865-6
通讯作者Li, Jingao(lijingao@hotmail.com) ; Hu, Chaosu(hucsu62@163.com)
英文摘要Penpulimab is an anti-programmed cell death-1 (PD-1) IgG1 antibody with no Fc gamma receptor (Fc gamma R) binding activity, and thus theoretically reduced immune-related adverse events (irAEs) while maintaining efficacy. This single-arm, phase II trial conducted across 20 tertiary care centers in China enrolled adult patients with metastatic nasopharyngeal carcinoma (NPC) who had failed two or more lines of previous systemic chemotherapy. Patients received 200-mg penpulimab intravenously every 2 weeks (4 weeks per cycle) until disease progression or intolerable toxicities. The primary endpoint was objective response rate (ORR) per RECIST (version 1.1), as assessed by an independent radiological review committee. The secondary endpoints included progression-free survival (PFS) and overall survival (OS). One hundred thirty patients were enrolled and 125 were efficacy evaluable. At the data cutoff date (September 28, 2022), 1 patient achieved complete response and 34 patients attained partial response. The ORR was 28.0% (95% CI 20.3-36.7%). The response was durable, with 66.8% still in response at 9 months. Thirty-three patients (26.4%) were still on treatment. The median PFS and OS were 3.6 months (95% CI = 1.9-7.3 months) and 22.8 months (95% CI = 17.1 months to not reached), respectively. Ten (7.6%) patients experienced grade 3 or higher irAEs. Penpulimab has promising anti-tumor activities and acceptable toxicities in heavily pretreated metastatic NPC patients, supporting further clinical development as third-line treatment of metastatic NPC.
WOS关键词T-CELL-ACTIVATION ; ANTITUMOR-ACTIVITY ; RECURRENT ; PEMBROLIZUMAB ; MONOTHERAPY ; SAFETY
资助项目Akeso Biopharma, Inc.
WOS研究方向Biochemistry & Molecular Biology ; Cell Biology
语种英语
WOS记录号WOS:001249607900002
出版者SPRINGERNATURE
资助机构Akeso Biopharma, Inc.
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/136533]  
专题中国科学院合肥物质科学研究院
通讯作者Li, Jingao; Hu, Chaosu
作者单位1.Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Radiat Oncol, Canc Hosp, Hangzhou, Peoples R China
3.Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Hunan Canc Hosp,Gastroenterol & Urol Dept 2, Changsha, Peoples R China
4.Clin Res Ctr Gastrointestinal Canc Hunan Prov, Changsha, Peoples R China
5.Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Dept Med Oncol, Guangzhou, Peoples R China
6.Guangxi Med Univ, Affiliated Tumor Hosp, Dept Radiat Oncol, Nanning, Peoples R China
7.Guangxi Med Univ, Key Lab Early Prevent & Treatment Reg High Frequen, Minist Educ, Nanning, Peoples R China
8.Guangxi Med Univ, Guangxi Key Lab Early Prevent & Treatment Reg High, Nanning, Peoples R China
9.Xiamen Univ, Affiliated Hosp 1, Canc Ctr, Dept Radiat Oncol, Xiamen, Peoples R China
10.Shantou Univ, Canc Hosp, Dept Med Oncol, Med Coll, Shantou, Peoples R China
推荐引用方式
GB/T 7714		 Chen, Xiaozhong,Wang, Wei,Zou, Qingfeng,et al. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study[J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY,2024,9.
APA Chen, Xiaozhong.,Wang, Wei.,Zou, Qingfeng.,Zhu, Xiaodong.,Lin, Qin.,...&Hu, Chaosu.(2024).Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.SIGNAL TRANSDUCTION AND TARGETED THERAPY,9.
MLA Chen, Xiaozhong,et al."Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study".SIGNAL TRANSDUCTION AND TARGETED THERAPY 9(2024).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。